Furosemide as a Cyclophosphamide Uroprotection Adjunct in Dogs
- Entry kind
- Supportive care
- Product family
- Cyclophosphamide bladder-protection strategies
Quick summary
furosemide used as a protocol adjunct is covered as loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
What it is
Loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy. Furosemide.
Active ingredients / formula
Furosemide.
Mechanism / rationale
Furosemide increases urine production, which can dilute and shorten bladder contact with acrolein, a urotoxic cyclophosphamide metabolite. It does not neutralise acrolein or protect marrow.
How it is discussed in tumor care
AAHA recommends administration with cyclophosphamide in dogs to decrease sterile haemorrhagic cystitis. This is a protocol relationship, not a reason to give a diuretic independently at home.
Potential role
AAHA recommends administration with cyclophosphamide in dogs to decrease sterile haemorrhagic cystitis. This is a protocol relationship, not a reason to give a diuretic independently at home.
Typical use context
Veterinarian-directed adjunct tied to the chemotherapy plan
Evidence snapshot
Retrospective canine studies found lower cystitis incidence with concurrent furosemide or mesna than without prophylaxis. Retrospective association does not establish zero risk, and metronomic and maximally tolerated protocols are not identical.
Safety notes
Diuresis can worsen dehydration, electrolyte imbalance, low blood pressure or kidney stress. Urinary obstruction or reduced access to water and elimination changes the risk substantially.
Interactions / cautions
Other diuretics, kidney-active medicines, NSAIDs and dehydration require review. Timing relative to cyclophosphamide and planned access to water and urination is part of the clinic protocol.
Regulatory status
This page describes extra-label protocol use; it is not an FDA-approved canine cancer indication for furosemide.
Regions, labels and market differences
Multi-region veterinary protocol use; local rules and practice vary.
Monitoring plan
The team assesses hydration, kidney values, electrolytes, urinary history and household ability to provide safe elimination. Owners monitor thirst, urination, weakness, vomiting and any blood or pain with urination. Suspected cystitis requires veterinary evaluation and may permanently change the chemotherapy plan.
Questions to ask your veterinarian
- Does the confirmed diagnosis and species match the evidence population?
- What is labelled, conditionally authorised or extra-label in this region?
- Which objective findings will define benefit, toxicity and a change in plan?
- What household handling, waste and urgent-contact instructions apply?